Nocodazole is an anti-microtubule agent for ABL, ABL (E255K) and ABL (T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM, respectively. Nocodazole is a high-affinity ligand for the cancer-related kinases including ABL phosphorylated, c-KIT, BRAF, and MEK with Kd of 0.091 μM, 1.6 μM, 1.8 μM and 1.6 μM, respectively. In addition, the Kd of Nocodazole for ABL (E255K) phosphorylated, ABL (T315I) phosphorylated, BRAF (V600E) and PI3Kγ is 0.12 μM, 0.17 μM, 1.1 μM and 1.5 μM, respectively. Nocodazole induces apoptosis in chronic lymphocytic leukemia cells. Nocodazole inhibits insulin-stimulated glucose transport. Nocodazole decreases apoptosis in some human colon carcinoma cells. Nocodazole impairs the morphology and directionality of migrating medial gan-glionic eminence cells. At high concentrations, nocodazole rapidly depolymerizes microtubules in cells, while low concentrations of nocodazole inhibit microtubule dynamic instability. Mitotic cells incubated with different concentrations of paclitaxel are inhibited from progressing to G1 phase 6 hours after release from the nocodazole block, with a median inhibitory concentration of 4 nM. Nocodazole-pretreated cells exposed to paclitaxel in the absence of nocodazole only form free-floating microtubules, whereas pretreated cells exposed to paclitaxel in the presence of nocodazole-assembled centrosome organize microtubules. Nocodazole disrupts microtubules by binding to β-tubulin. Nocodazole prevents the formation of one of the two interchain disulfide linkages. Nocodazole impairs the transport of vesicles. Nocodazole suppress METH-induced cell death and lysosomal dysfunction. METH-induced cell death is significantly decreased by Nocodazole pretreatment in comparison to METH alone. The tumor volume and tumor weight of the mice treated with Ketoconazole plus Nocodazole are significantly reduced as compared with those treated with Ketoconazole or Nocodazole alone. Combined treatment with Ketoconazole plus Nocodazole strongly enhances apoptosis of COLO 205 tumor xenografts treated with Ketoconazole or Nocodazole alone. The tumor volume and tumor weight of the mice treated with Ketoconazole plus Nocodazole are significantly reduced as compared with those treated with Ketoconazole or Nocodazole alone. Combined treatment with Ketoconazole plus Nocodazole strongly enhances apoptosis of COLO 205 tumor xenografts treated with Ketoconazole or Nocodazole alone.
Nat Methods. 2022 Mar;19(3):331-340.
Efficient targeted insertion of large DNA fragments without DNA donors
Nocodazole purchased from AbMole
|Animal models||Nude mice with COLO-205 tumor xenografts|
|Administration||Administered via i.p.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO 12 mg/mL|
|Related Src-bcr-Abl Products|
Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.
DGY-06-116 is an irreversible covalent and selective inhibitor of Src with IC50 of 2.6 nM.
RK-24466 (KIN 001-51) is a potent and selective inhibitor of Lck that inhibits two constructs of the human lck kinase, lck (64-509) and lckcd with IC50 of < 0.001 μM and 0.002 μM, respectively.
UM-164 is a highly potent, dual c-Src/p38inhibitor of c-Src with a binding constant Kd of 2.7 nM for c-Src and inhibits both p38α and p38β.
TP0427736 is a potent inhibitor of ALK5 kinase activity with an IC50 of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC50 = 836 nM for ALK3). It also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC50 value of 8.68 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.